Format

Send to

Choose Destination
See comment in PubMed Commons below
Cell Mol Biol (Noisy-le-grand). 2017 Mar 31;63(3):40-44. doi: 10.14715/cmb/2017.63.3.8.

The effects of CDKN2A rs3731249, rs11515, and rs3088440 polymorphisms on cancer risk.

Author information

1
The Third Department of Radiotherapy, Jilin Provincial Tumor Hospital, Changchun 130012, Jilin, China.
2
Department of Anesthesiology, The First Hospital of Jilin University, Changchun 130000, Jilin, China.
3
Department of Internal Medicine, Jilin Provincial Tumor Hospital, Changchun 130012, Jilin, China.
4
Department of Orthopaedics, The First Hospital of Jilin University, Changchun 130000, Jilin, China.

Abstract

Many studies have been carried out to examine whether there is an association between CDKN2A polymorphisms and cancer risk, but the results from these studies were controversial. In the present study, we performed a meta-analysis to clarify whether there is an association of CDKN2A polymorphisms and cancer risk. Published reports were searched in PubMed and Google Scholar. ORs with 95% CIs were calculated in the dominant models. Twenty six case-control studies that met the inclusion criteria were included in the final meta-analysis. Overall, we found that rs3731249, rs11515, and rs3088440 polymorphisms were not associated with cancer risk (OR=1.27, 95%CI: 0.79-2.03; OR=0.91, 95%CI: 0.79-1.03; OR=1.02, 95%CI: 0.95-1.09). However, CDKN2A rs3731249 polymorphism was significantly associated with ovarian cancer risk (OR=0.78, 95%CI: 0.65-0.95). A significant association was observed in Asian with rs11515 polymorphism (OR=0.48, 95%CI: 0.28-0.83). This meta-analysis shows that CDKN2A rs3731249 polymorphism was significantly associated with ovarian cancer risk. In addition, CDKN2A rs11515 polymorphism might associate with cancer risk in Asians.

KEYWORDS:

CDKN2A; Cancer; Meta-analysis.

PMID:
28466822
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Loading ...
    Support Center